Aspect Medical conducting "targeted" launch of Bispectral Index for anesthesia monitoring, CEO says.
This article was originally published in The Gray Sheet
Executive Summary
ASPECT MEDICAL BISPECTRAL INDEX FOR ANESTHESIA MONITORING initial market release is aimed to "establish this technology in some leading sites that are either market leaders or part of major hospital organizations today," company president and CEO Nassib Chamoun told investors Dec. 2 at the Robertson Stephens medical conference in New York City.
You may also be interested in...
Aspect BIS “Awareness” Indication Supported By Three Studies
An expanded indication for Aspect Medical's BIS bispectral index anesthesia monitoring technology for "reducing the risk of intraoperative awareness with recall" will be a competitive advantage, although the impact on sales remains undetermined, the firm says
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.